Table 3.
Treatments delivered in known vs latent BRCA1/2 mutation carriers.
| Known carriers N = 96 |
Latent carriers N = 202 |
|||||
|---|---|---|---|---|---|---|
| BRCA1 | BRCA2 | P-value | BRCA1 | BRCA2 | P-value | |
|
Number of patients (%) |
73 (76)a |
23 (24) |
118 (58) |
84 (42) |
||
| Chemotherapy, No. (%) | 46 (48) | 162 (80) | <0.00001 | |||
| Overall | 38/73 (52) | 8/23 (35) | 0.2276 | 99/118 (84) | 63/84 (75) | 0.166 |
| Adjuvant | 29/38 (76) | 5/8 (63) | 52/99 (52.5) | 36/63 (57) | ||
| Neoadjuvant | 9/38 (24) | 3/8 (37) | 47/99 (47.5) | 27/63 (43) | ||
| Refused recommended treatment b |
3 |
0 |
2 |
0 |
||
| Chemotherapy by tumor types | ||||||
| Triple-negative disease | 31/38 (81.6) | 3/8 (37.5) | 0.0325 | 78/99 (79) | 19/63 (30) | 0.0057 |
| ER-positive Her2-negative | 3/38 (7.9) | 4/8 (50) | 0.0134 | 13/99 (13) | 34/63 (54) | 0.0001 |
| Her2-positive | 4/38 (10.5) | 1/8 (12.5) | 0.8705 | 8/99 (8) | 10/63 (16) | 0.1998 |
|
Surgery, No. (%) |
||||||
| Lumpectomy only | 21/73 (28.2) | 13/23 (56.5) | 0.0295 | 50/118 (42.4) | 46/84 (54.8) | 0.1167 |
| Unilateral Mastectomy | 1/73 (1.4) | 1/23 (4.3) | 0.9722 | 10/118 (8.5) | 10/84 (11.9) | 0.5717 |
| Synchronous bilateral mastectomy as primary surgery | 36/73 (49.3) | 8/23 (34.8) | 0.3272 | 26/118 (22) | 10/84 (11.9) | 0.0954 |
| Metachronous bilateral mastectomy following lumpectomy | 15/73 (20.5) | 1/23 (4.3) | 0.1344 | 32/118 (27.1) | 14/84 (16.7) | 0.1151 |
| No surgery |
4c |
|||||
|
Radiotherapy, No. (%) |
41 (42.7) |
168 (83.2) |
<0.00001 |
|||
| Overall | 27/73 (37) | 14/23 (61) | 96/118 (81.4) | 73/84 (87) | ||
| Post-lumpectomy, node-negative disease | 20/27 (74) | 10/14 (71) | 0.8561 | 34/96 (35) | 31/71 (44) | 0.3576 |
| Post-lumpectomy with regional nodal radiation | 1/27 (4) | 1/14 (7) | 0.6278 | 36/96 (37.5) | 23/71 (32) | 0.604 |
| Postmastectomy radiation | 6/27 (22) | 3/14 (21) | 0.9536 | 27/96 (28) | 17/71 (24) | 0.66811 |
Abbreviations: DCIS, ductal carcinoma in situ.
a
Including 2 carriers of both BRCA1 and BRCA2 mutations.
b
All patients had triple-negative disease, two of them with stage T1bN0 and one with stage T1cN0.
c
Metastatic at presentation.